Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bradley Galer

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The Journal of Pain|November 19, 2003
Herpes zoster itch: preliminary epidemiologic dataAnne Louise Oaklander, David Bowsher, Bradley Galer, et al.
Epilepsy & Behavior : E&B|January 10, 2022
Fenfluramine modulates the anti-amnesic effects induced by sigma-1 receptor agonists and neuro(active)steroids in vivoParthena Martin, Tangui Maurice, Arnold Gammaitoni, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|February 4, 2021
Fenfluramine responder analyses and numbers needed to treat: Translating epilepsy trial data into clinical practiceJoseph Sullivan, M Scott Perry, James W Wheless, et al.
Epilepsy & Behavior : E&B|March 15, 2020
Fenfluramine acts as a positive modulator of sigma-1 receptorsParthena Martin, Peter A M de Witte, Tangui Maurice, et al.
Pain|December 28, 2010
Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic painDavid J Hewitt, Tony W Ho, Bradley Galer, et al.
Epilepsia|October 20, 2020
Fenfluramine HCl (Fintepla<sup>®</sup> ) provides long-term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension studyJoseph Sullivan, Ingrid E Scheffer, Lieven Lagae, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The Journal of Pain|November 19, 2003
Herpes zoster itch: preliminary epidemiologic dataAnne Louise Oaklander, David Bowsher, Bradley Galer, et al.
Epilepsy & Behavior : E&B|January 10, 2022
Fenfluramine modulates the anti-amnesic effects induced by sigma-1 receptor agonists and neuro(active)steroids in vivoParthena Martin, Tangui Maurice, Arnold Gammaitoni, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|February 4, 2021
Fenfluramine responder analyses and numbers needed to treat: Translating epilepsy trial data into clinical practiceJoseph Sullivan, M Scott Perry, James W Wheless, et al.
Epilepsy & Behavior : E&B|March 15, 2020
Fenfluramine acts as a positive modulator of sigma-1 receptorsParthena Martin, Peter A M de Witte, Tangui Maurice, et al.
Pain|December 28, 2010
Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic painDavid J Hewitt, Tony W Ho, Bradley Galer, et al.
Epilepsia|October 20, 2020
Fenfluramine HCl (Fintepla<sup>®</sup> ) provides long-term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension studyJoseph Sullivan, Ingrid E Scheffer, Lieven Lagae, et al.
Pageof 1